InvestorsHub Logo
Followers 30
Posts 640
Boards Moderated 0
Alias Born 01/17/2022

Re: hyperopia post# 453463

Wednesday, 03/23/2022 9:47:04 AM

Wednesday, March 23, 2022 9:47:04 AM

Post# of 701520
hyperopia, thx for the science perspectives, it is exciting to see that NWBO and Dr LL have a more comprehensive research program investigating therapy options which will determine therapy enhancements.

The science NWBO has pursued from the jump with DC's being the base tool still appears to be the correct way to utilize the power of nature. Car-T is just a way around DC's in a sense and more typical of BP research.

NWBO has taken the long road but their basic research, headed by Dr LL, will propel oncology into a much more holistic, natural, comprehensive, safer approach with better results. It is reassuring to see NWBO working on their platform to deepen it and to expand it. Their work not only can open more future doors but can also assist in their BLA submission MOA and risk analysis work to RA's.

I am assuming they are at least 1-2 yrs ahead of what we are seeing, maybe more. Their work to connect with other aspects of oncological science can also assist with company connections if they pursue partnership(s).

GLTA




















Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News